DTIL CFO reports RSU vesting and 1,303-share sale under 10b5-1

Rhea-AI Filing Summary

Precision BioSciences (DTIL) reported insider activity by CFO John Alexander Kelly. On November 2, 2025, 3,605 RSUs vested and settled, resulting in the acquisition of 3,605 common shares at $0. On November 3, 2025, he sold 1,303 shares at $6.49 under a Rule 10b5-1 plan as a sell-to-cover for tax withholding tied to the RSU vesting. Following these transactions, he beneficially owns 77,298 shares.

Insider Trade Summary

Net Seller: 1,303 shares ($8,456)

Net Sell 3 txns

Insider Kelly John Alexander

Role Chief Financial Officer

Sold 1,303 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,303	$6.49	$8K
Exercise	Restricted Stock Units	3,605	$0.00	--
Exercise	Common Stock	3,605	$0.00	--

Holdings After Transaction: Common Stock — 77,298 shares (Direct); Restricted Stock Units — 0 shares (Direct)

Footnotes (1)

1. Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Includes 1,511 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a price of $4.17 The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly John Alexander

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW STREET, SUITE A-100

(Street)

DURHAM NC 27701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2025		M		3,605(1)	A	$0(2)	78,601(3)	D
Common Stock	11/03/2025		S(4)		1,303	D	$6.49	77,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	11/02/2025		M			3,605	(5)	(5)	Common Stock	3,605	$0	0	D

Explanation of Responses:

1. Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. Includes 1,511 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a price of $4.17

4. The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

5. On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

Remarks:

	/s/ Dario Scimeca, Attorney-in-fact for John Alexander Kelly	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DTIL’s CFO report?

John Alexander Kelly reported the vesting and settlement of 3,605 RSUs on November 2, 2025, and the sale of 1,303 shares at $6.49 on November 3, 2025.

How many DTIL shares does the CFO own after the transactions?

After the reported transactions, he beneficially owns 77,298 shares.

Was the DTIL share sale under a 10b5-1 plan?

Yes. The sale was effected under a Rule 10b5-1 plan and was a sell-to-cover for tax withholding related to the RSU vesting.

What price were the DTIL shares sold for?

The 1,303 shares were sold at $6.49 per share.

What do the vested RSUs represent for DTIL’s CFO?

Each RSU represents a contingent right to receive one share of common stock; 3,605 RSUs vested and settled into shares.

Are there details on prior share acquisitions by the CFO?

Yes. Holdings include 1,511 shares acquired under the 2019 Employee Stock Purchase Plan at $4.17 per share.